SCENESSE® To Be Evaluated in Xeroderma Pigmentosum Variant (XPV)
CLINUVEL today announced that it has reached agreement with clinical and academic...
Read More
SCENESSE® Granted Market Access In Israel
CLINUVEL today announced that SCENESSE® (afamelanotide 16mg) has been added to the...
Read More
Media Release – CLINUVEL to Trial Innovative Drug in Stroke
The drug afamelanotide will be used for the first time in patients...
Read More
Media Release – TGA approves Australian drug to protect patients from light and sun
New Australian-developed drug approved by TGA for metabolic disorder erythropoietic protoporphyria (EPP)...
Read More
Australian TGA approves SCENESSE®
Executive summary SCENESSE® approved by Australian TGA under Priority Review First approved...
Read More
Media Release - First patient dosed in SCENESSE® DNA Repair Program
Xeroderma pigmentosum (XP) patient receives SCENESSE® treatment In the search for a...
Read More
Media Release (ASX) - CLINUVEL progresses innovative DNA Repair Program
Drug tested to protect skin and regenerate DNA, firstly in XP patients...
Read More
Media Release – New drug to repair damaged skin and reduce skin cancer risk
Figure 1: CLINUVEL’s DNA Repair Program aims to confirm that intervention with...
Read More
SCENESSE® in DNA Repair
CLINUVEL to confirm cellular DNA repair in rare disease xeroderma pigmentosum (XP)...
Read More
Media Release - Second Afamelanotide Formulation
PRÉNUMBRA®- CLINUVEL’S SECOND AFAMELANOTIDE FORMULATION Drug to be evaluated in patients with...
Read More